Podhorna Jana, Krahnke Tillmann, Shear Michael, Harrison John E
Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173, Ingelheim/Rhein, 55218, Germany.
Cogitars GmbH, Heidelberg, Germany.
Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.
Development of new treatments for Alzheimer's disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in patients with mild to moderate AD. Attempts to improve its properties for early AD by removing items prone to ceiling and/or by adding cognitive measures known to be impaired early have yielded a number of ADAS-Cog variants. Using Alzheimer's Disease Neuroimaging Initiative data, we compared the performance of the 3-, 5-, 11- and 13-item ADAS-Cog variants in subjects with early AD. Given the interest in enrichment strategies, we also examined this aspect with a focus on cerebrospinal fluid (CSF) markers.
Subjects with mild cognitive impairment (MCI) and mild AD with available ADAS-Cog 13 and CSF data were analysed. The decline over time was defined by change from baseline. Direct cross-comparison of the ADAS-Cog variants was performed using the signal-to-noise ratio (SNR), with higher values reflecting increased sensitivity to detect change over time.
The decline over time on any of the ADAS-Cog variants was minimal in subjects with MCI. Approximately half of subjects with MCI fulfilled enrichment criteria for positive AD pathology. The impact of enrichment was detectable but subtle in MCI. The annual decline in mild AD was more pronounced but still modest. More than 90 % of subjects with mild AD had positive AD pathology. SNRs were low in MCI but greater in mild AD. The numerically largest SNRs were seen for the ADAS-Cog 5 in MCI and for both the 5- and 13-item ADAS-Cog variants in mild AD, although associated confidence intervals were large.
The possible value of ADAS-Cog expansion or reduction is less than compelling, particularly in MCI. In mild AD, adding items known to be impaired at early stages seems to provide more benefit than removing items on which subjects score close to ceiling.
阿尔茨海默病(AD)新治疗方法的研发已扩展到对认知轻度受损且衰退缓慢的个体进行早期干预。阿尔茨海默病评估量表 - 认知分量表(ADAS - Cog)的11项版本最初是为测量轻度至中度AD患者的认知而开发的。通过去除易出现天花板效应的项目和/或添加已知早期受损的认知测量方法来改善其对早期AD的适用性,已产生了许多ADAS - Cog变体。利用阿尔茨海默病神经影像学倡议数据,我们比较了3项、5项、11项和13项ADAS - Cog变体在早期AD患者中的表现。鉴于对富集策略的兴趣,我们还以脑脊液(CSF)标志物为重点研究了这一方面。
分析有可用ADAS - Cog 13和CSF数据的轻度认知障碍(MCI)和轻度AD患者。随时间的衰退通过与基线的变化来定义。使用信噪比(SNR)对ADAS - Cog变体进行直接交叉比较,值越高表明检测随时间变化的敏感性增加。
MCI患者中任何ADAS - Cog变体随时间的衰退都很小。约一半的MCI患者符合AD病理阳性的富集标准。富集的影响在MCI中可检测到但很细微。轻度AD患者的年度衰退更明显但仍较轻微。超过90%的轻度AD患者有阳性AD病理。MCI中的SNR较低,但在轻度AD中较高。MCI中ADAS - Cog 5的SNR数值最大,轻度AD中5项和13项ADAS - Cog变体的SNR数值最大,尽管相关的置信区间很大。
ADAS - Cog扩展或缩减的潜在价值并不令人信服,尤其是在MCI中。在轻度AD中,添加已知早期受损的项目似乎比去除受试者得分接近天花板的项目更有益。